Hitoden (Hydrocortisone)

Hitoden is indicated for several endocrine and immune‑mediated conditions where glucocorticoid therapy is appropriate.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute adrenal crisis when rapid glucocorticoid effect is needed.
• Adjunctive treatment of inflammatory disorders such as rheumatoid arthritis, systemic lupus erythematosus, and severe dermatitis.
• Control of autoimmune conditions that require systemic immunosuppression, for example, vasculitis or inflammatory bowel disease.
• Short‑term use in severe allergic reactions or asthma exacerbations when oral therapy is preferred.

• Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After oral absorption, the drug diffuses into cells and binds to the receptor complex, inducing conformational changes that allow translocation to the nucleus. There, it modulates gene transcription by up‑regulating anti‑inflammatory proteins (e.g., annexin‑1) and down‑regulating pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6, and tumor necrosis factor‑α, resulting in reduced inflammation and immune activity.

Oral hydrocortisone may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common

• Increased appetite or gradual weight gain, often accompanied by fluid retention.
• Mild gastrointestinal discomfort such as nausea, dyspepsia, or abdominal fullness.
• Peripheral edema due to sodium and water retention, usually noticeable in the lower extremities.
• Mood alterations including irritability, anxiety, or mild insomnia, especially during dose adjustments.

Serious

• Marked hyperglycemia that may precipitate or worsen diabetes mellitus, requiring glucose monitoring.
• Severe hypertension or cardiovascular events, including increased risk of myocardial infarction or stroke.
• Accelerated loss of bone mineral density leading to osteoporosis and a higher risk of fractures.
• Suppression of the hypothalamic‑pituitary‑adrenal axis, which can cause adrenal insufficiency if the drug is stopped abruptly.

Before initiating Hitoden, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate therapy.

• Assess for existing infections, as glucocorticoids can exacerbate bacterial, viral, or fungal diseases.
• Evaluate blood glucose and blood pressure, especially in patients with diabetes or cardiovascular disease.
• Consider bone health; long‑term use may increase the risk of osteoporosis and fractures.
• Review history of psychiatric disorders, since corticosteroids can affect mood and behavior.
• Use the lowest effective dose for the shortest duration necessary to achieve therapeutic goals.
• Monitor for signs of adrenal suppression during tapering or after prolonged therapy.

Hydrocortisone can influence the pharmacokinetics or pharmacodynamics of several other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure.
• Simultaneous administration of systemic anticoagulants (e.g., warfarin) where glucocorticoid‑induced changes in clotting factors could increase bleeding risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because combined use may raise the risk of gastrointestinal ulceration or bleeding.
• Antidiabetic agents, as hydrocortisone may raise blood glucose and require dose adjustments.
• Antihypertensive medications, since fluid retention can diminish their effectiveness.
• Vaccines, particularly live attenuated vaccines, because immunosuppression may reduce vaccine efficacy.